TY - JOUR
T1 - Prediction of short-term antidepressant response using probabilistic graphical models with replication across multiple drugs and treatment settings
AU - Athreya, Arjun P.
AU - Brückl, Tanja
AU - Binder, Elisabeth B.
AU - John Rush, A.
AU - Biernacka, Joanna
AU - Frye, Mark A.
AU - Neavin, Drew
AU - Skime, Michelle
AU - Monrad, Ditlev
AU - Iyer, Ravishankar K.
AU - Mayes, Taryn
AU - Trivedi, Madhukar
AU - Carter, Rickey E.
AU - Wang, Liewei
AU - Weinshilboum, Richard M.
AU - Croarkin, Paul E.
AU - Bobo, William V.
N1 - Funding Information:
MT: Consulting/advising ACADIA Pharmaceuticals, Alkermes Inc, Allergan, Alto Neuroscience Inc, Applied Clinical Intelligence LLC, Axsome Therapeutics, Boegringer Ingelheim, Engage Health Media, GreenLight VitalSign6 Inc, Janssen, Lundbeck Research USA, Navitor Pharmaceutical Inc, Otsuka, Perception Neuroscience, Pharmerit International, and SAGE Therapeutics. Edditorial Compensation from American Psychiatric Association (Deputy Editor for American Journal of Psychiatry), Oxford University Press. Receives funding from NIMH, NIDA, Patient-Centered Outcomes Research Institute (PCORI), Cancer Prevention Research Institute of Texas (CPRIT). AJR has received consulting fees from Akili, Brain Resource Inc., Compass Inc., Curbstone Consultant LLC, Emmes Corp., Johnson and Johnson (Janssen), Liva-Nova, Mind Linc, Otsuka America Pharmaceutical Inc., Sunovion; speaking fees from Liva-Nova; and royalties from Guilford Press and the University of Texas Southwestern Medical Center, Dallas, TX (for the Inventory of Depressive Symptoms and its derivatives). He is also named coinventor on two patents: U.S. Patent No. 7,795,033: Methods to Predict the Outcome of Treatment with Antidepressant Medication, Inventors: McMahon FJ, Laje G, Manji H, Rush AJ, Paddock S, Wilson AS; and U.S. Patent No. 7,906,283: Methods to Identify Patients at Risk of Developing Adverse Events During Treatment with Antidepressant Medication, Inventors: McMahon FJ, Laje G, Manji H, Rush AJ, Paddock S. MAF has grant support from AssureRx, the Mayo Foundation, Myriad, the National Institute of Alcohol Abuse and Alcoholism (NIAAA), the National Institute of Mental Health (NIMH), and Pfizer, and consults for Janssen, Mitsubishi Tanabe Pharma Corporation, Myriad, Neuralstem Inc., Otsuka America Pharmaceutical, Sunovion, and Teva Pharmaceuticals. LW and RMW are co-founders and stockholders in OneOme LLC. WVB’s research has been supported by the National Institute of Mental Health, the Agency for Healthcare Quality and Research, and the Mayo Foundation for Medical Education and Research. He has contributed chapters to UpToDate concerning the use of antidepressants and atypical antipsychotic drugs for treating adults with bipolar major depression. APA receives support from the Mayo Foundation for Medical Education and Research. Rest of the authors have no conflicts to disclose. This material is based upon work partially supported by a Mayo Clinic and Illinois Alliance Fellowship for Technology-Based Healthcare Research; a CompGen Fellowship; an IBM Faculty Award; the National Science Foundation (NSF) under grants 2041339 and 1337732; the National Institutes of Health (NIH) under grants R01 AA27486, R01 MH113700, U19 GM61388, R01 GM28157, RC2 GM092729, R24 GM078233, RC2 GM092729, and T32 GM072474; and the Mayo Clinic Center for Individualized Medicine. Any opinions, findings, and conclusions or recommendations expressed in this material are those of the author(s) and do not necessarily reflect the views of the NSF or the NIH.
Publisher Copyright:
© 2021, The Author(s).
PY - 2021/6
Y1 - 2021/6
N2 - Heterogeneity in the clinical presentation of major depressive disorder and response to antidepressants limits clinicians’ ability to accurately predict a specific patient’s eventual response to therapy. Validated depressive symptom profiles may be an important tool for identifying poor outcomes early in the course of treatment. To derive these symptom profiles, we first examined data from 947 depressed subjects treated with selective serotonin reuptake inhibitors (SSRIs) to delineate the heterogeneity of antidepressant response using probabilistic graphical models (PGMs). We then used unsupervised machine learning to identify specific depressive symptoms and thresholds of improvement that were predictive of antidepressant response by 4 weeks for a patient to achieve remission, response, or nonresponse by 8 weeks. Four depressive symptoms (depressed mood, guilt feelings and delusion, work and activities and psychic anxiety) and specific thresholds of change in each at 4 weeks predicted eventual outcome at 8 weeks to SSRI therapy with an average accuracy of 77% (p = 5.5E-08). The same four symptoms and prognostic thresholds derived from patients treated with SSRIs correctly predicted outcomes in 72% (p = 1.25E-05) of 1996 patients treated with other antidepressants in both inpatient and outpatient settings in independent publicly-available datasets. These predictive accuracies were higher than the accuracy of 53% for predicting SSRI response achieved using approaches that (i) incorporated only baseline clinical and sociodemographic factors, or (ii) used 4-week nonresponse status to predict likely outcomes at 8 weeks. The present findings suggest that PGMs providing interpretable predictions have the potential to enhance clinical treatment of depression and reduce the time burden associated with trials of ineffective antidepressants. Prospective trials examining this approach are forthcoming.
AB - Heterogeneity in the clinical presentation of major depressive disorder and response to antidepressants limits clinicians’ ability to accurately predict a specific patient’s eventual response to therapy. Validated depressive symptom profiles may be an important tool for identifying poor outcomes early in the course of treatment. To derive these symptom profiles, we first examined data from 947 depressed subjects treated with selective serotonin reuptake inhibitors (SSRIs) to delineate the heterogeneity of antidepressant response using probabilistic graphical models (PGMs). We then used unsupervised machine learning to identify specific depressive symptoms and thresholds of improvement that were predictive of antidepressant response by 4 weeks for a patient to achieve remission, response, or nonresponse by 8 weeks. Four depressive symptoms (depressed mood, guilt feelings and delusion, work and activities and psychic anxiety) and specific thresholds of change in each at 4 weeks predicted eventual outcome at 8 weeks to SSRI therapy with an average accuracy of 77% (p = 5.5E-08). The same four symptoms and prognostic thresholds derived from patients treated with SSRIs correctly predicted outcomes in 72% (p = 1.25E-05) of 1996 patients treated with other antidepressants in both inpatient and outpatient settings in independent publicly-available datasets. These predictive accuracies were higher than the accuracy of 53% for predicting SSRI response achieved using approaches that (i) incorporated only baseline clinical and sociodemographic factors, or (ii) used 4-week nonresponse status to predict likely outcomes at 8 weeks. The present findings suggest that PGMs providing interpretable predictions have the potential to enhance clinical treatment of depression and reduce the time burden associated with trials of ineffective antidepressants. Prospective trials examining this approach are forthcoming.
UR - http://www.scopus.com/inward/record.url?scp=85100014047&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85100014047&partnerID=8YFLogxK
U2 - 10.1038/s41386-020-00943-x
DO - 10.1038/s41386-020-00943-x
M3 - Article
C2 - 33452433
AN - SCOPUS:85100014047
SN - 0893-133X
VL - 46
SP - 1272
EP - 1282
JO - Neuropsychopharmacology
JF - Neuropsychopharmacology
IS - 7
ER -